Cogstate (ASX.CGS), via its global commercial partner Eisai Co., Ltd, is pleased to announce that Cogstate technology will be marketed in Japan as a pre-installed application on a smartphone used widely by the senior population.
From February 2022, the Raku-Raku smartphone will be shipped with a version of Cogstate’s computerised assessment of cognition, called NouKNOW, pre-installed on the device. The Raku-Raku smartphone is marketed to the senior population in Japan and has shipped more than 7 million units.
NouKNOW (pronounced noh-noh) is a digital tool for self-assessment of brain health based upon technology created by Cogstate, which utilises a selection of cognitive assessments known collectively as the “Cogstate Brief Battery”. The Japanese product launch of NouKNOW occurred on 31 March 2020. https://nouknow.jp/
A copy of the press release can be found here.
Eisai – Cogstate Japan Agreement
On 28 August 2019, Cogstate announced that it had entered into an agreement with pharmaceutical company, Eisai Co., Ltd., to distribute Cogstate technology in Japan. Under the exclusive licensing agreement, Eisai is marketing Cogstate technology as a digital cognitive assessment tool for cognition in Japanese markets. The agreement specifically excludes clinical trials, where Cogstate will continue to market its offering independently.
Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.